For the Inventor, By the Inventor

Enter assignee name

Munich, Germany

Amgen Research (Munich) Gmbh

USPTO Granted Patents = 77

% Expired Patents = 2.6

Trademarks = 1

Forward Citations = 467

Loading Chart...

Loading Chart...

138 inventors (with patents filed for the assignee):

Peter Kufer (49 out of 65 patents)

Tobias Raum (49 out of 60 patents)

Patrick Hoffmann (37 out of 39 patents)

4. Doris Rau (23 out of 27 patents)

5. Ralf Lutterbüse (20 out of 26 patents)

6. Roman Kischel (19 out of 22 patents)

7. Claudia Blümel (17 out of 17 patents)

8. Elisabeth Nahrwold (13 out of 13 patents)

9. Gerhard Zugmaier (11 out of 12 patents)

10. Christoph Dahlhoff (11 out of 11 patents)

11. Andreas Wolf (10 out of 16 patents)

12. Dirk Nagorsen (10 out of 11 patents)

13. Matthias Klinger (9 out of 10 patents)

14. Susanne Mangold (8 out of 9 patents)

15. Jochen Pendzialek (8 out of 8 patents)

Core Competencies:

Bispecific Antibody

CD3

BCMA

DLL3

T Cell Engaging

Pharmaceutical Composition

Antibody Constructs

Cancer Treatment

Cross-Species Specific

Anti-CCR8

EGFRVIII

MUC17

77 patents: Sort by Forward Citations

1. 12735484 - Bispecific single chain antibodies with specificity for high molecular weight target antigens (2026-09-15),

2. 12617853 - Low pH pharmaceutical composition comprising T cell engaging antibody constructs (2026-05-05),

3. 12441796 - Antibody constructs for CDH19 and CD3 (2025-10-14),

4. 12435139 - Antibody constructs for DLL3 and CD3 (2025-10-07),

5. 12428491 - PSMA and CD3 bispecific T cell engaging antibody constructs (2025-09-30),

6. 12312412 - MAGEB2 binding constructs (2025-05-27),

7. 12304952 - Antibody constructs for DLL3 and CD3 (2025-05-20),

8. 12297292 - Antibody constructs for CDH19 and CD3 (2025-05-13),

9. 12281176 - Binding molecules for BCMA and CD3 (2025-04-21),

10. 12281175 - Binding molecules for BCMA and CD3 (2025-04-21),

11. 12281172 - Cross-species-specific PSMAxCD3 bispecific single chain antibody (2025-04-21),

12. 12258411 - Anti-CCR8 antibodies and uses thereof (2025-03-25),

13. 12258404 - Bispecific antibody construct directed to MUC17 and CD3 (2025-03-25),

14. 12152078 - Nucleic acids encoding anitbody constructs binding EGFR VIII and CD3 (2024-11-26),

15. 11987633 - Cross-species-specific single domain bispecific single chain antibody (2024-05-21),

Amgen Research (Munich) GmbH specializes in the development of bispecific antibody constructs, focusing on innovative approaches to cancer treatment. The company leverages advanced technologies in T cell engagement, targeting specific proteins such as CD3, BCMA, and DLL3 to enhance therapeutic efficacy. Located in Munich, Germany, Amgen Research is dedicated to pioneering pharmaceutical compositions that address complex medical challenges, contributing to the advancement of targeted therapies in oncology.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Amgen Research (Munich) Gmbh

77 Patents

#59 in W-8000 Munich

#746 in Germany

#9,761 in the World

Munich, Germany

Amgen Research (Munich) Gmbh

Forward Citations = 467

138 inventors:

Peter Kufer (49 out of 65 patents)

Tobias Raum (49 out of 60 patents)

Patrick Hoffmann (37 out of 39 patents)

4. Doris Rau (23 out of 27 patents)

5. Ralf Lutterbüse (20 out of 26 patents)

Please report any incorrect information to [email protected]

Loading…